AI Article Synopsis
- This update discusses recent advancements in treatments for myasthenia gravis, including the FDA approval of the Fc receptor inhibitor efgartigimod.
- It highlights risks and considerations related to corticosteroid use, such as treatment initiation and tapering, along with the implications of antibody overshoot after plasmapheresis.
- Additionally, the update reviews the role of acetylcholine receptor antibodies in diagnosing ocular myasthenia, addresses concerns regarding myasthenia gravis during pregnancy, and examines case reports involving Lambert-Eaton myasthenic syndrome and its related conditions.
Article Abstract
This update covers a number of treatment topics starting with Fc receptor inhibitors and the Federal Drug Administration approval of efgartigimod. Some uncertainties regarding the use of corticosteroids are addressed, namely the risk of exacerbation with initiation of treatment and how to taper. The presence and potential importance of antibody overshoot following plasmapheresis is noted and the evolving increase in usefulness of acetylcholine receptor antibodies in diagnosing ocular myasthenia. Several recent series and case reports regarding coronavirus 2019 and myasthenia gravis are reviewed. The topics of myasthenia gravis and pregnancy, and another look at thymectomy in MG are provided. Finally, a couple of case reports on Lambert-Eaton myasthenic syndrome concentrate on the ice pack test and an autoantibody association with paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome in the same patient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CND.0000000000000403 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!